![]() |
||||||||||||||||
|
||||||||||||||||
![]() |
||||||||||||||||
| Last Trade | 1.88 | Trade Time | 6/19/2013 10:48:00 AM |
| Change | -0.02
|
Volume (thou) | 39.874 |
| %Change | -1.05% | Last Trade Size | |
| Open | 1.85 | Bid | 1.88 |
| Today's High | 1.9 | Ask | 1.9 |
| Today's Low | 1.85 | Size Bid/Ask | 13 x16 |
Fundamental Data |
|||
| Market Cap (mil) | 47618.52 | 52 Week High | 5.86 |
| Shrs Outstanding (thou) | 25329000 | 52 Week Low | 1.70 |
| EPS | -0.31 | PE Ratio | .00 |
| Volatility | Yield | .00 | |
| Dividend Freq. | 0 | Ex-Dividend Date | 10/5/2012 |
| Dividend Amount | 0.16667 | Exchange | NASDAQ GM |
| Delayed quotes powered by S&P comstock. All stock quotes are delayed by 20 minutes and are believed to be accurate but are not warranted or guaranteed by MENAFN.com | |||
![]() |
Jun 06, 2013 | Aeterna Zentaris Announces Dismissal of Class Action Lawsuit, CNW Group |
![]() |
Jun 05, 2013 | Sama Resources Appoints Marcel Aubut and Richard Quesnel Directors and Corporate Update, Marketwire |
![]() |
Jun 05, 2013 | Sama Resources Appoints Marcel Aubut and Richard Quesnel Directors and Corporate Update, Marketwire Canada |
![]() |
Jun 03, 2013 | Aeterna Zentaris: Encouraging Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin (AEZS-108) in Prostate Cancer Reported at ASCO, CNW Group |
![]() |
May 23, 2013 | Aeterna Zentaris: Posters to be Presented on Phase 1 and Phase 2 Trials with AEZS-108 in Prostate and Breast Cancer at Upcoming ASCO Meeting, CNW Group |
![]() |
May 21, 2013 | Aeterna Zentaris Announces "At-the-Market" Issuance Program, CNW Group |
more... |
||
| MENAFN News | Market Data | Countries | Tools | Section | |||
|
Main News News By Industry News By Country Marketwatch News UPI News Comtex News |
Market Indices Quotes & Charts Currencies Cross Rates |
Algeria
Bahrain Egypt Iraq Jordan Kuwait Lebanon Morocco Oman Palestine Qatar Saudi Arabia Syria Tunisia UAE Yemen |
Weather |
Corporate Monitor
Arab Research |
|||
© 2000 menafn.com All Rights Reserved.
Terms of Service | Privacy
Policy | Contact Us | Advertise
| About MENAFN | Career
Opportunities | Feedback | Help
|
|||||||